Literature DB >> 14966153

A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: the SPES/SCOPA.

J Marinus1, M Visser, A M Stiggelbout, J Martin Rabey, P Martínez-Martín, U Bonuccelli, P H Kraus, J J van Hilten.   

Abstract

OBJECTIVES: To evaluate the reliability and validity of the Short Parkinson's Evaluation Scale (SPES)/SCales for Outcomes in Parkinson's disease (SCOPA)-a short scale developed to assess motor function in patients with Parkinson's disease (PD).
METHODS: Eighty five patients with PD were assessed with the SPES/SCOPA, Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn and Yahr (H&Y) scale, and Schwab and England (S&E) scale. Thirty four patients were examined twice by two different assessors who were blinded to each other's scores and test executions. Additionally, six items of the motor section of the SPES/SCOPA were assessed in nine patients and recorded on videotape to evaluate inter-rater and intra-rater reliability.
RESULTS: The reproducibility of the sum scores in the clinical assessments was high for all subscales of the SPES/SCOPA. Inter-rater reliability coefficients for individual items ranged from 0.27-0.83 in the motor impairment section, from 0.58-0.82 in the activities of daily living section, and from 0.65-0.92 in the motor complications section. Inter-rater reliability of the motor items in the video assessments ranged from 0.70-0.87 and intra-rater reliability ranged from 0.81-0.95. The correlation between related subscales of the SPES/SCOPA and UPDRS were all higher than 0.85, and both scales revealed similar correlations with other measures of disease severity. The mean time to complete the scales differed significantly (p<0.001) and measured 8.1 (SD 1.9) minutes for the SPES/SCOPA and 15.6 (SD 3.6) minutes for the UPDRS.
CONCLUSION: The SPES/SCOPA is a short, reliable, and valid scale that can adequately be used in both research and clinical practice.

Entities:  

Mesh:

Year:  2004        PMID: 14966153      PMCID: PMC1738938          DOI: 10.1136/jnnp.2003.017509

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

2.  The disablement process.

Authors:  L M Verbrugge; A M Jette
Journal:  Soc Sci Med       Date:  1994-01       Impact factor: 4.634

3.  Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination.

Authors:  M Richards; K Marder; L Cote; R Mayeux
Journal:  Mov Disord       Date:  1994-01       Impact factor: 10.338

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

Review 5.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

6.  Pramipexole in patients with early Parkinson's disease.

Authors:  J P Hubble; W C Koller; N R Cutler; J J Sramek; J Friedman; C Goetz; A Ranhosky; D Korts; A Elvin
Journal:  Clin Neuropharmacol       Date:  1995-08       Impact factor: 1.592

7.  [Pramipexole in Parkinson disease. Results of a treatment observation].

Authors:  H Reichmann; H M Brecht; P H Kraus; M R Lemke
Journal:  Nervenarzt       Date:  2002-08       Impact factor: 1.214

8.  Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.

Authors:  J J van Hilten; A D van der Zwan; A H Zwinderman; R A Roos
Journal:  Mov Disord       Date:  1994-01       Impact factor: 10.338

9.  Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group.

Authors:  P Martínez-Martín; A Gil-Nagel; L M Gracia; J B Gómez; J Martínez-Sarriés; F Bermejo
Journal:  Mov Disord       Date:  1994-01       Impact factor: 10.338

10.  Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.

Authors:  Andrew Siderowf; Michael McDermott; Karl Kieburtz; Karen Blindauer; Sandra Plumb; Ira Shoulson
Journal:  Mov Disord       Date:  2002-07       Impact factor: 10.338

View more
  41 in total

1.  Lack of association of morphologic and functional retinal changes with motor and non-motor symptoms severity in Parkinson’s disease.

Authors:  Esther Cubo; María Jesús López Peña; Elio Diez-Feijo Varela; Olga Pérez Gil; Pablo Garcia Gutierrez; Elena Araus González; Rosa Prieto Tedejo; Natividad Mariscal Pérez; Diana Armesto
Journal:  J Neural Transm (Vienna)       Date:  2014-02       Impact factor: 3.575

2.  Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.

Authors:  Ganqiang Liu; Joseph J Locascio; Jean-Christophe Corvol; Brendon Boot; Zhixiang Liao; Kara Page; Daly Franco; Kyle Burke; Iris E Jansen; Ana Trisini-Lipsanopoulos; Sophie Winder-Rhodes; Caroline M Tanner; Anthony E Lang; Shirley Eberly; Alexis Elbaz; Alexis Brice; Graziella Mangone; Bernard Ravina; Ira Shoulson; Florence Cormier-Dequaire; Peter Heutink; Jacobus J van Hilten; Roger A Barker; Caroline H Williams-Gray; Johan Marinus; Clemens R Scherzer
Journal:  Lancet Neurol       Date:  2017-06-16       Impact factor: 44.182

3.  A short scale for evaluation of neuropsychiatric disorders in Parkinson's disease: first psychometric approach.

Authors:  Pablo Martinez-Martin; Belen Frades-Payo; Luis Agüera-Ortiz; Angel Ayuga-Martinez
Journal:  J Neurol       Date:  2012-04-18       Impact factor: 4.849

4.  Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.

Authors:  Nir Giladi; Anthony P Nicholas; Mahnaz Asgharnejad; Elisabeth Dohin; Franz Woltering; Lars Bauer; Werner Poewe
Journal:  J Parkinsons Dis       Date:  2016-10-19       Impact factor: 5.568

5.  A comprehensive model of health-related quality of life in Parkinson's disease.

Authors:  M Visser; S M van Rooden; D Verbaan; J Marinus; A M Stiggelbout; J J van Hilten
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

Review 6.  Instruments for holistic assessment of Parkinson's disease.

Authors:  Pablo Martinez-Martin
Journal:  J Neural Transm (Vienna)       Date:  2013-03-10       Impact factor: 3.575

7.  Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Authors:  Pablo Martinez-Martin; Carmen Rodriguez-Blazquez; Mario Alvarez-Sanchez; Tomoko Arakaki; Alberto Bergareche-Yarza; Anabel Chade; Nelida Garretto; Oscar Gershanik; Monica M Kurtis; Juan Carlos Martinez-Castrillo; Amelia Mendoza-Rodriguez; Henry P Moore; Mayela Rodriguez-Violante; Carlos Singer; Barbara C Tilley; Jing Huang; Glenn T Stebbins; Christopher G Goetz
Journal:  J Neurol       Date:  2012-08-05       Impact factor: 4.849

8.  Cognitive impairment in Parkinson's disease.

Authors:  D Verbaan; J Marinus; M Visser; S M van Rooden; A M Stiggelbout; H A M Middelkoop; J J van Hilten
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04-18       Impact factor: 10.154

9.  The Parkinson's Disease Sleep Scale-2 (PDSS-2): Validation of the Spanish Version and Its Relationship With a Roommate-Based Version.

Authors:  Pablo Martinez-Martin; John B Wetmore; Carmen Rodríguez-Blázquez; Tomoko Arakaki; Oscar Bernal; Victor Campos-Arillo; Christopher Cerda; Ingrid Estrada-Bellmann; Nélida Garretto; Letty Ginsburg; Jorge Uriel Máñez-Miró; Juan Carlos Martínez-Castrillo; Ivonne Pedroso; Marcos Serrano-Dueñas; Carlos Singer; Mayela Rodríguez-Violante; Francisco Vivancos
Journal:  Mov Disord Clin Pract       Date:  2019-03-18

10.  Exercise therapy, quality of life, and activities of daily living in patients with Parkinson disease: a small scale quasi-randomised trial.

Authors:  Bahram Yousefi; Vahid Tadibi; Ali Fathollahzadeh Khoei; Ali Montazeri
Journal:  Trials       Date:  2009-08-11       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.